Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis  Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and

Ambiq Announces Pricing of Initial Public Offering Ambiq Announces Pricing of Initial Public Offering AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the pricing of its upsized initial public offering of 4,000,000 shares of

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for